Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 9/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18283692 | 0.92 | GSK3B (0.35) | DRD4SIGMAR1GABRA1GABRB2 | |
| SCHEMBL16196214 | 0.88 | MEN1 (0.42) | MEN1KMT2ACYP2D6CYP1A2DRD4 | |
| SCHEMBL23612062 | 0.85 | GSK3B (0.34) | GABRA1GABRB2 | |
| SCHEMBL15244435 | 0.83 | MEN1 (0.39) | IRAK4MEN1KMT2ACYP2D6CYP1A2 | |
| SCHEMBL23038642 | 0.82 | HRH3 (0.37) | IRAK4MEN1KMT2ACYP2D6CYP1A2 | |
| SCHEMBL15244341 | 0.82 | MEN1 (0.38) | IRAK4MEN1KMT2ACYP2D6CYP1A2 | |
| SCHEMBL22518575 | 0.81 | LRRK2 (0.39) | MEN1KMT2ACYP2D6CYP1A2DRD4 | |
| SCHEMBL23612287 | 0.79 | GSK3B (0.31) | GABRA1GABRB2 | |
| SCHEMBL174612 | 0.79 | F2 (0.41) | MEN1KMT2ADRD4SIGMAR1 | |
| SCHEMBL23612179 | 0.78 | F2 (0.36) | MEN1KMT2AGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479555-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase | NEWAVE PHARMACEUTICAL INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-20210061807-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDINE-3-ONE COMPOUNDS AS INHIBITORS OF WEE-1 KINASE | NEWAVE PHARMACEUTICAL INC. | 2021-03-04 | — | — | US | disclosed |
| WO-2019165204-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDINE-3-ONE COMPOUNDS AS INHIBITORS OF WEE-1 KINASE | NEWAVE PHARMACEUTICAL INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061807-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDINE-3-ONE COMPOUNDS AS INHIBITORS OF WEE-1 KINASE | WEE1, WEE2, PEAK1 | HSP90AA1 1644/4885IRAK4 469/4885MEN1 853/4885 |
| US-11479555-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase | WEE1, WEE2, PHKG1 | HSP90AA1 1671/4885IRAK4 430/4885MEN1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.